ALKBH3 inhibition normalizes neovessels by reprogramming endothelial fate in diabetic microvasculopathy

Proceedings of the National Academy of Sciences, Volume 123, Issue 34, August 2026. <br/>SignificanceDiabetic microvasculopathy drives organ damage worldwide, with diabetic retinopathy (DR) as a leading cause of blindness. Current anti-vascular endothelial growth factor (VEGF) therapies only suppress abnormal vessel growth but fail to … Source: Read the original article on www.pnas.org